The virus comes in through the vaginal lining and wastes no time. Within hours, herpes simplex virus 2 has slipped into nerve endings, riding them up into the dense clusters of cells near the base of the spine, where it settles in for good. Once it reaches those ganglia, no drug evicts it. It simply waits, flaring up when it pleases, shedding silently the rest of the time. This is why genital herpes, which affects more than half a billion people worldwide, has stayed one step ahead of vaccine makers for the better part of forty years.
The trouble has never really been a shortage of effort. It has been geography.
A flu shot in the arm trains your immune system beautifully, but the soldiers it produces patrol the bloodstream and the lymph nodes. They are not standing guard at the vaginal mucosa, the actual doorway the virus uses. By the time circulating defenders arrive, herpes has already booked passage to the nervous system. Generations of recombinant glycoprotein vaccines, injected the conventional way, foundered on exactly this gap: good systemic immunity, hardly any at the border that matters.
Akiko Iwasaki’s lab at Yale has been chipping at this problem for years with a tactic she calls “prime and pull”. Prime the body systemically, then pull immune cells to the right tissue with a chemical lure.
The pulling, it turned out, was the hard part. Iwasaki’s team had tried coaxing immune cells to the vaginal lining using chemokines, the small proteins that act as the immune system’s signposts. It worked, sort of. Cells showed up, disease eased, but the protection was only partial because it never engaged B cells, the antibody factories you need to actually neutralise the virus at the surface. A second approach used a snippet of immune-stimulating DNA called CpG, a known trigger of an innate alarm receptor. That one knocked the virus down hard. It also inflamed the tissue something rotten.
“We had these two really promising strategies in the lab, but each had some shortcoming,” says Sachin Bhagchandani, a postdoc in Iwasaki’s lab who led the work. “So we set out to formulate a particle that could overcome those shortcomings.”
Two flawed tools, fused into one
What Bhagchandani built is a nanoparticle the team named BEACON. The trick is almost elegant in its simplicity: the CpG DNA carries a negative charge, and the chemokine they chose, CXCL9, carries a positive one, so the two snap together electrostatically into stable little spheres roughly 150 to 200 nanometres across. The chemokine still does its signposting job, the DNA still sounds its alarm, but now they arrive at the same place at the same time, bundled. And because the package is sized and charged to be swallowed preferentially by antigen-presenting cells, the immune system’s professional messengers, far less of it ends up provoking the inflammatory neutrophils that caused the earlier mess. The team measured roughly a tenfold jump in uptake by the cells they wanted and about half the uptake by the ones they didn’t. Less CpG, better aimed, meant the inflammation largely vanished.
That balance was not a given. Build the particle from the wrong chemokine, CXCL10 rather than CXCL9, and it falls apart into useless aggregates; the researchers traced the difference to a stretch of CXCL9’s tail, a cationic C-terminal region that does the molecular stitching.
“Sachin led this work, creating a nanoparticle that was stable and effective, which was no small feat,” says Iwasaki, who is also an investigator with the Howard Hughes Medical Institute.
The regimen runs in two acts. First a conventional intramuscular shot of mRNA, the same lipid-nanoparticle technology behind the covid vaccines, encoding a herpes surface protein. Then, a few weeks later, the pull: the matching protein delivered straight to the vaginal tissue alongside BEACON.
What stays behind
In mice, the payoff showed up where it counts. Animals that got the local boost built up dense populations of CD8 tissue-resident memory T cells, the kind of immune cell that takes up permanent residence in a tissue rather than recirculating, plus a strong local supply of antibodies in the vaginal mucosa. When the researchers later exposed the mice to live virus, 80 per cent of the prime-and-pull group sailed through six months with no sign of disease. Among mice that got the standard intramuscular booster instead, only 40 per cent did. Viral genetic material in those vulnerable nerve clusters dropped around 80-fold in the boosted animals, and tellingly, the molecular signature of latency, the transcript the virus produces while lying dormant, was absent altogether. The virus had barely got a foothold.
“That showed us that this approach could be profoundly impactful, establishing local immune responses for a significantly long period of time,” says Bhagchandani.
There are caveats worth keeping in view. When the team stripped out either the T cells or the B cells, protection collapsed, which means both arms have to be present and working, a more demanding requirement than a single-target vaccine. Mice are not people; their reproductive tracts do not cycle, harbour the same microbes, or face repeated real-world exposure. And the study tested prevention, not whether the method could quiet an infection someone already carries, which is arguably what most of the half-billion would want.
Still, the implications stretch well beyond herpes. The same logic, prime broadly then concentrate the response at a mucosal surface, could in principle be pointed at other sexually transmitted infections that have shrugged off injected vaccines, HIV and chlamydia among them. The team is already working with Stanford’s Appel lab to turn BEACON into something a person could actually use, a vaginal suppository being the obvious candidate. They are also testing a version delivered through the nose, which would do the pulling at the nasal lining and, crucially, open the approach up to men.
Iwasaki keeps returning to the part that has nothing to do with immunology. So much of what herpes patients endure, she points out, is not physical at all but mental and societal, the weight of a stigma attached to an infection that is nobody’s fault. A vaccine that worked would lift more than a viral load.
DOI / Source: 10.1126/sciimmunol.aea6419, Science Immunology
Frequently Asked Questions
Why can’t a normal injected vaccine stop genital herpes?
A standard shot builds immunity in the blood and lymph nodes, but the herpes virus enters through the vaginal lining and reaches the nervous system within hours. Circulating immune cells arrive too late to stop that journey. The new approach works by stationing immune cells and antibodies directly in the mucosal tissue where infection actually begins.
How does the BEACON nanoparticle actually work?
It binds a piece of immune-stimulating DNA called CpG to a chemokine called CXCL9 using their opposite electrical charges, forming a stable particle. The chemokine recruits immune cells to the tissue while the DNA activates them, and the particle is built to be taken up mainly by helpful immune cells rather than the inflammatory ones that plagued earlier attempts. That targeting let researchers use far less DNA and avoid the tissue inflammation seen before.
Could this ever work for men?
Potentially, yes. The current version delivers the second dose vaginally, but the team is testing a nasal version that would recruit immune cells at the nose instead. If that works, the same prime-and-pull logic could be applied to men as well.
Is this close to being available for people?
Not yet. The results so far come from mice, and human reproductive biology differs in ways that could affect the outcome. Researchers are collaborating with a Stanford lab to develop a practical formulation such as a suppository, with human clinical trials as a longer-term goal.